<p>StockNews.com 的分析師在週一發佈的研究報告中開始覆蓋 Cytosorbents（NASDAQ:CTSO - 獲取免費報告）的股票。該公司對這家醫療研究公司的股票給予了 “持有” 評級。</p>
<p>Cytosorbents 最近成為其他多份研究報告的主題。HC Wainwright 在 11 月 11 日的報告中重申了 “中性” 評級，並對 Cytosorbents 的股票設定了 1.00 美元的目標價。D. Boral Capital 在 2 月 25 日的報告中重申了 “買入” 評級，並對 Cytosorbents 的股票設定了 10.00 美元的目標價。兩位研究分析師對該股票給予了持有評級，兩位給予了買入評級，還有一位給予了強烈買入評級。根據 MarketBeat.com 的數據，該公司的共識評級為 “適度買入”，平均目標價為 4.67 美元。</p>
<p><strong>閲讀我們對 Cytosorbents 的最新股票分析</strong></p>
<h2>Cytosorbents 股價下跌 3.8%</h2>
<p>Cytosorbents 股票週一開盤價為 1.01 美元。該公司的市值為 5523 萬美元，市盈率為 -2.81，貝塔值為 0.78。Cytosorbents 的 12 個月最低價為 0.70 美元，最高價為 1.61 美元。該公司的 50 日移動平均價格為 1.05 美元，200 日移動平均價格為 1.05 美元。公司的流動比率為 1.97，速動比率為 1.58，債務與股本比率為 1.06。</p>
<h2>Cytosorbents 的機構交易</h2>
<p>最近，一些對沖基金和其他機構投資者對該公司的持倉進行了調整。Millennium Management LLC 在第四季度收購了 Cytosorbents 的新股份，價值約 30,000 美元。Northern Trust Corp 在第四季度將其在 Cytosorbents 的持股增加了 22.3%。Northern Trust Corp 目前擁有 91,560 股該醫療研究公司的股票，價值 83,000 美元，此前在上個季度又購買了 16,701 股。Avenir Corp 在第四季度將其在 Cytosorbents 的持股增加了 4.0%。Avenir Corp 目前擁有 3,093,946 股該醫療研究公司的股票，價值 2,815,000 美元，此前在上個季度又購買了 118,387 股。Raymond James Financial Inc. 在第四季度收購了 Cytosorbents 的新股份，價值約 99,000 美元。最後，Renaissance Technologies LLC 在第四季度將其在 Cytosorbents 的持股增加了 10.6%。Renaissance Technologies LLC 目前擁有 88,020 股該醫療研究公司的股票，價值 80,000 美元，此前在上個季度又購買了 8,400 股。機構投資者和對沖基金持有該公司 32.87% 的股票。</p>
<h2>關於 Cytosorbents</h2>
<p>(獲取免費報告)</p>
<p>Cytosorbents Corporation 從事醫療設備的研究、開發和商業化，其血液淨化技術平台結合了專有的吸附劑和多孔聚合物技術，業務遍及美國、德國及國際市場。其旗艦產品為 CytoSorb，一種用於膿毒症治療的體外細胞因子吸附器，作為輔助治療，適用於其他重症護理應用、預防和治療圍手術期併發症，以及維持或增強從供體處獲取的固體器官的質量以進行器官移植；並提供 VetResQ，一種用於動物膿毒症、胰腺炎和其他危重病症的輔助治療設備。</p>
<h2>推薦故事</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Cytosorbents</li>
<li>賣空：如何做空股票</li>
<li>機構投資者在這四隻股票上下注 10 億美元——你應該買嗎？</li>
<li>投資旅遊股票的好處</li>
<li>在關税衝擊市場時，必須購買的股票和必須避免的股票</li>
<li>如何一步步購買便宜股票</li>
<li>這四隻科技 ETF 剛剛觸及 50 日低點——現在是買入時機嗎？</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Cytosorbents 嗎？</h2>
<p>在你考慮 Cytosorbents 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄推薦給客户的股票，建議現在購買，以便在更廣泛的市場注意到之前……而 Cytosorbents 並不在名單上。</p>
<p>雖然 Cytosorbents 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

CTSO

<p>StockNews.com 在週一的一份研究報告中開始對 CytoSorbents 的股票進行覆蓋。他們對該股票給予了 “持有” 評級</p>

<p>Analysts at StockNews.com initiated coverage on shares of Cytosorbents (NASDAQ:CTSO - Get Free Report) in a research note issued on Monday. The firm set a &#34;hold&#34; rating on the medical research company's stock.</p>
<div class="lb-trans"><p>StockNews.com 的分析師在週一發佈的研究報告中開始覆蓋 Cytosorbents（NASDAQ:CTSO - 獲取免費報告）的股票。該公司對這家醫療研究公司的股票給予了 “持有” 評級。</p>
</div><p>CTSO has been the subject of a number of other research reports. HC Wainwright reiterated a &#34;neutral&#34; rating and issued a $1.00 price objective on shares of Cytosorbents in a report on Monday, November 11th. D. Boral Capital reiterated a &#34;buy&#34; rating and issued a $10.00 price objective on shares of Cytosorbents in a report on Tuesday, February 25th. Two research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $4.67.</p>
<div class="lb-trans"><p>Cytosorbents 最近成為其他多份研究報告的主題。HC Wainwright 在 11 月 11 日的報告中重申了 “中性” 評級，並對 Cytosorbents 的股票設定了 1.00 美元的目標價。D. Boral Capital 在 2 月 25 日的報告中重申了 “買入” 評級，並對 Cytosorbents 的股票設定了 10.00 美元的目標價。兩位研究分析師對該股票給予了持有評級，兩位給予了買入評級，還有一位給予了強烈買入評級。根據 MarketBeat.com 的數據，該公司的共識評級為 “適度買入”，平均目標價為 4.67 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on Cytosorbents</strong></p>
<div class="lb-trans"><p><strong>閲讀我們對 Cytosorbents 的最新股票分析</strong></p>
</div><h2>Cytosorbents Trading Down 3.8 %</h2>
<div class="lb-trans"><h2>Cytosorbents 股價下跌 3.8%</h2>
</div><p>Shares of Cytosorbents stock opened at $1.01 on Monday. The firm has a market capitalization of $55.23 million, a PE ratio of -2.81 and a beta of 0.78. Cytosorbents has a twelve month low of $0.70 and a twelve month high of $1.61. The firm's 50-day moving average price is $1.05 and its 200 day moving average price is $1.05. The company has a current ratio of 1.97, a quick ratio of 1.58 and a debt-to-equity ratio of 1.06.</p>
<div class="lb-trans"><p>Cytosorbents 股票週一開盤價為 1.01 美元。該公司的市值為 5523 萬美元，市盈率為 -2.81，貝塔值為 0.78。Cytosorbents 的 12 個月最低價為 0.70 美元，最高價為 1.61 美元。該公司的 50 日移動平均價格為 1.05 美元，200 日移動平均價格為 1.05 美元。公司的流動比率為 1.97，速動比率為 1.58，債務與股本比率為 1.06。</p>
</div><h2>Institutional Trading of Cytosorbents</h2>
<div class="lb-trans"><h2>Cytosorbents 的機構交易</h2>
</div><p>A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Millennium Management LLC acquired a new stake in shares of Cytosorbents during the 4th quarter worth approximately $30,000. Northern Trust Corp increased its holdings in shares of Cytosorbents by 22.3% during the 4th quarter. Northern Trust Corp now owns 91,560 shares of the medical research company's stock worth $83,000 after buying an additional 16,701 shares during the last quarter. Avenir Corp increased its holdings in shares of Cytosorbents by 4.0% during the 4th quarter. Avenir Corp now owns 3,093,946 shares of the medical research company's stock worth $2,815,000 after buying an additional 118,387 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Cytosorbents during the 4th quarter worth approximately $99,000. Finally, Renaissance Technologies LLC increased its holdings in shares of Cytosorbents by 10.6% during the 4th quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company's stock worth $80,000 after buying an additional 8,400 shares during the last quarter. Institutional investors and hedge funds own 32.87% of the company's stock.</p>
<div class="lb-trans"><p>最近，一些對沖基金和其他機構投資者對該公司的持倉進行了調整。Millennium Management LLC 在第四季度收購了 Cytosorbents 的新股份，價值約 30,000 美元。Northern Trust Corp 在第四季度將其在 Cytosorbents 的持股增加了 22.3%。Northern Trust Corp 目前擁有 91,560 股該醫療研究公司的股票，價值 83,000 美元，此前在上個季度又購買了 16,701 股。Avenir Corp 在第四季度將其在 Cytosorbents 的持股增加了 4.0%。Avenir Corp 目前擁有 3,093,946 股該醫療研究公司的股票，價值 2,815,000 美元，此前在上個季度又購買了 118,387 股。Raymond James Financial Inc. 在第四季度收購了 Cytosorbents 的新股份，價值約 99,000 美元。最後，Renaissance Technologies LLC 在第四季度將其在 Cytosorbents 的持股增加了 10.6%。Renaissance Technologies LLC 目前擁有 88,020 股該醫療研究公司的股票，價值 80,000 美元，此前在上個季度又購買了 8,400 股。機構投資者和對沖基金持有該公司 32.87% 的股票。</p>
</div><h2>About Cytosorbents</h2>
<div class="lb-trans"><h2>關於 Cytosorbents</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.</p>
<div class="lb-trans"><p>Cytosorbents Corporation 從事醫療設備的研究、開發和商業化，其血液淨化技術平台結合了專有的吸附劑和多孔聚合物技術，業務遍及美國、德國及國際市場。其旗艦產品為 CytoSorb，一種用於膿毒症治療的體外細胞因子吸附器，作為輔助治療，適用於其他重症護理應用、預防和治療圍手術期併發症，以及維持或增強從供體處獲取的固體器官的質量以進行器官移植；並提供 VetResQ，一種用於動物膿毒症、胰腺炎和其他危重病症的輔助治療設備。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Cytosorbents</li>
<li>Short Selling: How to Short a Stock</li>
<li>Institutional Investors Bet $1B on These 4 Stocks—Should You?</li>
<li>Investing in Travel Stocks Benefits</li>
<li>One Must-Buy Stock and One to Avoid as Tariffs Shake the Market</li>
<li>How to Buy Cheap Stocks Step by Step</li>
<li>These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Cytosorbents</li>
<li>賣空：如何做空股票</li>
<li>機構投資者在這四隻股票上下注 10 億美元——你應該買嗎？</li>
<li>投資旅遊股票的好處</li>
<li>在關税衝擊市場時，必須購買的股票和必須避免的股票</li>
<li>如何一步步購買便宜股票</li>
<li>這四隻科技 ETF 剛剛觸及 50 日低點——現在是買入時機嗎？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Cytosorbents Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Cytosorbents 嗎？</h2>
</div><p>Before you consider Cytosorbents, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Cytosorbents 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cytosorbents wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄推薦給客户的股票，建議現在購買，以便在更廣泛的市場注意到之前……而 Cytosorbents 並不在名單上。</p>
</div><p>While Cytosorbents currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Cytosorbents 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

StockNews.com 開始對 CytoSorbents（納斯達克股票代碼：CTSO）進行報道